416 related articles for article (PubMed ID: 27746228)
1. Influence of the cooling rate and the blend ratio on the physical stability of co-amorphous naproxen/indomethacin.
Beyer A; Grohganz H; Löbmann K; Rades T; Leopold CS
Eur J Pharm Biopharm; 2016 Dec; 109():140-148. PubMed ID: 27746228
[TBL] [Abstract][Full Text] [Related]
2. Improvement of the physicochemical properties of Co-amorphous naproxen-indomethacin by naproxen-sodium.
Beyer A; Grohganz H; Löbmann K; Rades T; Leopold CS
Int J Pharm; 2017 Jun; 526(1-2):88-94. PubMed ID: 28392278
[TBL] [Abstract][Full Text] [Related]
3. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen.
Löbmann K; Laitinen R; Grohganz H; Gordon KC; Strachan C; Rades T
Mol Pharm; 2011 Oct; 8(5):1919-28. PubMed ID: 21815614
[TBL] [Abstract][Full Text] [Related]
4. Preparation and recrystallization behavior of spray-dried co-amorphous naproxen-indomethacin.
Beyer A; Radi L; Grohganz H; Löbmann K; Rades T; Leopold CS
Eur J Pharm Biopharm; 2016 Jul; 104():72-81. PubMed ID: 27130786
[TBL] [Abstract][Full Text] [Related]
5. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
6. Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions.
Dengale SJ; Ranjan OP; Hussen SS; Krishna BS; Musmade PB; Gautham Shenoy G; Bhat K
Eur J Pharm Sci; 2014 Oct; 62():57-64. PubMed ID: 24878386
[TBL] [Abstract][Full Text] [Related]
7. Investigation of physical properties and stability of indomethacin-cimetidine and naproxen-cimetidine co-amorphous systems prepared by quench cooling, coprecipitation and ball milling.
Lim AW; Löbmann K; Grohganz H; Rades T; Chieng N
J Pharm Pharmacol; 2016 Jan; 68(1):36-45. PubMed ID: 26663364
[TBL] [Abstract][Full Text] [Related]
8. A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin.
Löbmann K; Laitinen R; Grohganz H; Strachan C; Rades T; Gordon KC
Int J Pharm; 2013 Aug; 453(1):80-7. PubMed ID: 22613066
[TBL] [Abstract][Full Text] [Related]
9. Multivariate Quantification of the Solid State Phase Composition of Co-Amorphous Naproxen-Indomethacin.
Beyer A; Grohganz H; Löbmann K; Rades T; Leopold CS
Molecules; 2015 Oct; 20(10):19571-87. PubMed ID: 26516832
[TBL] [Abstract][Full Text] [Related]
10. Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine.
Kasten G; Nouri K; Grohganz H; Rades T; Löbmann K
Int J Pharm; 2017 Nov; 533(1):138-144. PubMed ID: 28947246
[TBL] [Abstract][Full Text] [Related]
11. Polymer incorporation method affects the physical stability of amorphous indomethacin in aqueous suspension.
Surwase SA; Itkonen L; Aaltonen J; Saville D; Rades T; Peltonen L; Strachan CJ
Eur J Pharm Biopharm; 2015 Oct; 96():32-43. PubMed ID: 26092472
[TBL] [Abstract][Full Text] [Related]
12. The formation and physical stability of two-phase solid dispersion systems of indomethacin in supercooled molten mixtures with different matrix formers.
Semjonov K; Kogermann K; Laidmäe I; Antikainen O; Strachan CJ; Ehlers H; Yliruusi J; Heinämäki J
Eur J Pharm Sci; 2017 Jan; 97():237-246. PubMed ID: 27890595
[TBL] [Abstract][Full Text] [Related]
13. Determination of Stable Co-Amorphous Drug-Drug Ratios from the Eutectic Behavior of Crystalline Physical Mixtures.
Kissi EO; Khorami K; Rades T
Pharmaceutics; 2019 Nov; 11(12):. PubMed ID: 31771255
[TBL] [Abstract][Full Text] [Related]
14. Reactive Melt Extrusion To Improve the Dissolution Performance and Physical Stability of Naproxen Amorphous Solid Dispersions.
Liu X; Zhou L; Zhang F
Mol Pharm; 2017 Mar; 14(3):658-673. PubMed ID: 28135108
[TBL] [Abstract][Full Text] [Related]
15. Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin-arginine.
Lenz E; Jensen KT; Blaabjerg LI; Knop K; Grohganz H; Löbmann K; Rades T; Kleinebudde P
Eur J Pharm Biopharm; 2015 Oct; 96():44-52. PubMed ID: 26197392
[TBL] [Abstract][Full Text] [Related]
16. Properties of the Sodium Naproxen-Lactose-Tetrahydrate Co-Crystal upon Processing and Storage.
Sovago I; Wang W; Qiu D; Raijada D; Rantanen J; Grohganz H; Rades T; Bond AD; Löbmann K
Molecules; 2016 Apr; 21(4):509. PubMed ID: 27104502
[TBL] [Abstract][Full Text] [Related]
17. [The development of co-amorphous drug systems].
Yao J; Shi NQ; Wang XL
Yao Xue Xue Bao; 2013 May; 48(5):648-54. PubMed ID: 23888685
[TBL] [Abstract][Full Text] [Related]
18. Relating hydrogen-bonding interactions with the phase behavior of naproxen/PVP K 25 solid dispersions: evaluation of solution-cast and quench-cooled films.
Paudel A; Nies E; Van den Mooter G
Mol Pharm; 2012 Nov; 9(11):3301-17. PubMed ID: 23009610
[TBL] [Abstract][Full Text] [Related]
19. Physical stability of API/polymer-blend amorphous solid dispersions.
Lehmkemper K; Kyeremateng SO; Bartels M; Degenhardt M; Sadowski G
Eur J Pharm Biopharm; 2018 Mar; 124():147-157. PubMed ID: 29269154
[TBL] [Abstract][Full Text] [Related]
20. Co-amorphous systems consisting of indomethacin and the chiral co-former tryptophan: Solid-state properties and molecular mobilities.
Holzapfel K; Rades T; Leopold CS
Int J Pharm; 2023 Apr; 636():122840. PubMed ID: 36921746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
